Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures

Seminars in Oncology

Volumn 29, Issue 5, 2002, Pages 21-33

  Gamelin, Erick ^a,b   Gamelin, Laurence ^a,b   Bossi, Laura ^a,b   Quasthoff, Stefan ^a,b  

^a CENTRE PAUL PAPIN   (France)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBOPLATIN; CIGUATOXIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GLUCONATE CALCIUM; ION CHANNEL; ISOPROTEIN; MAGNESIUM SULFATE; OXALIPLATIN; PLATINUM DERIVATIVE; SEROTONIN 3 ANTAGONIST; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; TETRAPLATIN; TETRODOTOXIN; VALPROIC ACID;

ARTICLE; ATAXIA; BLOOD TOXICITY; CELL MEMBRANE; CHANNEL GATING; CLINICAL FEATURE; CLINICAL TRIAL; COLD STRESS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DYSESTHESIA; FUNCTIONAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INFUSION; JAW; LIMB; MOTONEURON; MUSCLE CELL; MUSCLE CONTRACTION; NEPHROTOXICITY; NERVE CELL EXCITABILITY; NERVE FIBER DEGENERATION; NEUROTOXICITY; OTOTOXICITY; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NERVE CELL; TEMPERATURE DEPENDENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MUSCLE CELLS; NERVOUS SYSTEM DISEASES; NEURONS; ORGANOPLATINUM COMPOUNDS; SODIUM CHANNELS;

EID: 0037010088     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(02)90017-5     Document Type: Article

References (69)

1. Cerosimo R: Cisplatin neurotoxicity. Cancer Treat Rev 16:195-211, 1989
2. Mollman J: Cisplatin neurotoxicity. N Engl J Med 322:126-127, 1990
3. Hallmark R, Snyder J, Jusenius K, et al: Factors influencing ototoxicity in ovarian cancer patients treated with cisplatinum based chemotherapy. Eur J Gynaecol Oncol 13:35-44, 1992
4. Schaefer S, Post J, Close L, et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer 56:1934-1939, 1985
5. Waters G, Ahmad M, Katsarkas A, et al: Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear 12:91-102, 1991
6. Petersen P, Hansen S: The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-, seminomatous germ-cell cancer. Ann Oncol 10:1475-1483, 1991
7. Screnci D, McKeage M: Platinum neurotoxicity: clinical profils, experimental models and neuroprotective approaches. J Inorg Biochem 77:105-110, 1999
8. Krarup-Hansen A, Rietz B, Krarup C, et al: Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin An autopsy study. Neuropathol Appl Neurobiol 25:29-40, 1999
9. Tuxen M, Hansen S: Neurotoxicity secondary to antineoplastic drugs. Curr Ther Rev 20:191-214, 1994
10. Scott R, Woods A, Lacey M, et al: An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Naunyn Schmiedebergs Arch Pharmacol 352:247-255, 1995
11. Fiskum G: Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 17:843-855, 2000
12. Lu C, Fu W, Mattson M: Caspase-mediated suppression of glutamate (AMPA) receptor channel activity in hippocampal neurons in response to DNA damage promotes apoptosis and prevents necrosis: Implication for neurological side effects of cancer therapy and neurodegenerative disorders. Neurobiol Dis 8:194-206, 2001
13. Gill J, Windebank A: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842-2850, 1998
14. Canetta R, Rosenzweig M, Carter S: Carboplatin: The clinical spectrum to date. Cancer Treat Rev 12:125-136, 1985
15. Cavaletti G, Bogliun G, Zincone A, et al: Neuro- and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 18:3797-3802, 1998
16. Woynarowski J, Faivre S, Herzig M, et al: Oxaliptatin-induced damage of cellular DNA. Mol Pharmacol 58:920-927, 2000
17. O'Rourke T, Weiss G, New F, et al: Phase I clinical trial of ormaplatin (tetraplatin; NSC 363812). Anticancer Drugs 5:520-526, 1994
18. Schilder R, LaCreta F, Perez R, et al: Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res 54:709-717, 1994
19. Giacchetti S, Zidani R, Perpoint B, et al: Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:229a, 1997 (abstr)
20. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
21. Luo F, Wyrick S, Chaney S: Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44:19-28, 1999
22. Luo F, Wyrick S, Chaney S: Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol 44:29-38, 1999
23. Extra J, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
24. Extra J-M, Marty M, Brienza S, et al: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22, 1998 (suppl 5)
25. Moxley IR: Channelopathies. Curr Treat Opt Neurol 2:31-47, 2000
26. André T, Bensmaine M, Louver C, et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999
27. Taieb S, Freyer G, Rambaud L, et al: Central neurotoxicity induced by oxaliplatin: Report on 4 cases. Proc Am Soc Clin Oncol 19:312a, 2000 (abstr 1234)
28. Degardin M, Nguyen K-T, Carlier D, et al: Etude comparative de l'ototoxicité du cisplatine et de l'oxaliplatine chez les patients ayant un carcinome épidermoide des voies aerodigestives superieures. JFORL 46:292-296, 1997
29. Garufi C, Pietrangeli A, Brienza S, et al: Electrophysiological evaluation of oxaliplatin neurotoxicity. Proc Am Soc Clin Oncol 18:244a, 1999 (abstr 938)
30. Holmes J, Stanko J, Varchenko M, et al: Comparative neurotoxicity of oxaliplatin, cisplatin and ormaplatin in a Wistar rat model. Toxicol Sci 46:342-351, 1998
31. Cavaletti G, Tredici G, Petruccioli M, et al: Neurotoxicity of oxaliplatin (I-OHP) in rats and influence of scheduling. Clin Cancer Res 6:4537s, 2000 (abstr 356)
32. Murrie V, Gill J, Windebank A: Neurotoxic potential of platin compounds: role of cell cycle elements. Soc Neurosci 24:1794, 1998 (abstr)
33. Gutmann L, Gutmann L: Axonal channelopathies: An evolving concept in the pathogenesis of peripheral nerve disorders. Neurology 47:18-21, 1996
34. Weinreich F, Jentsch T: Neurological diseases caused by ion channel mutations. Curr Opin Neurobiol 10:409-415, 2000
35. Browne D, Gancher S, Nutt J, et al: Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat Genet 8:136-140, 1994
36. Vincent A, Lily O, Palace J: Pathogenic autoantibodies to neuronal proteins in neurological disorders. J Neuroimmunol 100:169-180, 1999
37. Hart J: Acquired neuromyotonia: A new antibody-mediated neuromuscular potassium channelopathy. Am J Med Sci 310:209-216, 2000
38. Hille B: Ionic Channels of Excitable Membranes (ed 2). Sunderland, MA, Sinauer, 1992
39. Lehmann-Horn F, Jurkat-Rott K: Voltage-gated ion channels and hereditary disease. Physiol Rev 79:1317-1372, 1999
40. Felts P, Yokoyama S, Dib-Hajj S, et al: Sodium channel alpha subunit mRNAs I, II, III NaG, Na6 and hNE (PN1): Different expression patterns in developing rat nervous system. Mol Brain Res 45:71-82, 1997
41. Waxman S, Cummins T, Dib-Hajj S, et al: Voltagegated sodium channels and the molecular pathogenesis of pain: A review. J Rehab Res Dev 37:517-528, 2000
42. Mogyoros I, Bostock H, Burke D: Mechanisms of paresthesias arising from healthy axons. Muscle Nerve 23:310-320, 2000
43. Matzner O, Devor M: Hyperexcitability at sites of nerve injury depends on voltage-sensitive Na+ channels. J Neurophysiol 72:349-359, 1994
44. Omana-Zapata I, Khabbaz M, Hunter J, et al: Tetrodotoxin inhibits neuropathic ectopic activity in neuromas, dorsal root ganglia and dorsal horn neurons. Pain 72:41-49, 1997
45. Waxman S, Kocsis J, Black J: Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 72:466-470, 1994
46. Barchi R: Ion channel mutations and diseases of skeletal muscle. Neurobiol Dis 4:254-264, 1997
47. Dib-Hajj S, Fjell J, Cummins T, et al: Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 83:591-600, 1999
48. + inactivation and bursting discharges in a simple model axon: Implication for neuropathic pain. Brain Res 754:221-226, 1997
49. + channel heterogeneity. Eur Neurol 36:3-12, 1996
50. Pearn J: Neurology of ciguatera. J Neurol Neurosurg Psychiatry 70:4-8, 2001
51. + channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25-32, 2000
52. Boughattas N: Effects of the anticancer agent oxaliplatin on the excitability properties of the peripheral nervous system. Proc Am Assoc Cancer Res 35:433, 1994 (abstr 2583)
53. Cvitkovic E, Bekradda M: Oxaliplatin: A new therapeutic option in colorectal cancer. Semin Oncol 26:647-662, 1999
54. Grolleau F, Gamelin L, Boisdron-Celle M, et al: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293-2297, 2001
55. Gamelin L, Grolleau F, Boisdron-Celle M, et al: Acute neurotoxicity of oxaliplatin: Effects on neuronal voltage-gated sodium channels. Proc Am Assoc Cancer Res 20:42, 2001 (abstr 5020)
56. Obrenovich T: Neuroprotective strategies: voltagegated Na+ channel down-modulation versus presynaptic glutamate release inhibition. Rev Neurosci 9:203-211, 1998
57. Taylor C, Narasimhan L: Sodium channels and therapy of central nervous system diseases. Adv Pharmacol 39:47-98, 1997
58. Levy R, Mattson R, Memdrum B: Antiepileptic drugs (ed 4). New York, NY, Raven Press, 1995
59. Willow M, Kuentzel E, Catterall W: Inhibition of voltage-gated sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 25:228-234, 1984
60. Beghi E: The use of anticonvulsants in neurological conditions other than epilepsy. A review of the evidence from randomized controlled trials. CNS Drugs 11:61-82, 1999
61. Sechi G, Traccis S, Durelli L, et al: Carbamazepine versus diphenylhydantoin in the treatment of myotonia. Eur Neurol 22:113-118, 1983
62. Lersch C, Eckel F, Assmann G, et al: Prevention of peripheral sensory neuropathy (PSN) by carbamazepine in patients with advanced colorectal cancers (ACRC) treated with oxaliplatin, a pilot study. Gastroenterology 118:A522, 2000 (suppl 2) (abstr 2776)
63. Macdonald R, Kelly K: Antiepileptic drug mechanisms of action. Epilepsia 35:S19-S28, 1993 (suppl 4)
64. Honmou O, Kocsis J, Richerson G: Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 20:193-202, 1995
65. Mariani G, Garrone O, Granetto C, et al: Oxaliplatin-induced neuropathy: Could gabapentin be the answer. Proc Am Soc Clin Oncol 19:609a, 2000 (abstr 2397)
66. + channels and its effect on closing rate. Proc Natl Acad Sci U S A 96:4154-4157, 1999
67. Lajer H, Daugaard G: Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47-58, 1999
68. Laiń-Cessac P, Boisdron-CelIe, M, Girault C, et al: Acute oxaliplatin neurotoxicity dramatically improved with intravenous calcium and magnesium salts. Presented at lleme congŕs annuel de la Société Française de Pharmacologie, March 23-25, 1998, Nancy, France
69. ++ chloride infusions - A retrospective study. Proc Am Soc Clin Oncol 21:157a, 2002 (abstr 624)